Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on developing novel immuno-neurology therapies for neurodegenerative diseases. The company's approach targets the immune system as a central mechanism for treating Alzheimer's disease and other conditions.
| Attribute |
Value |
| Ticker |
NASDAQ: ALEC |
| Founded |
2013 |
| Headquarters |
South San Francisco, CA, USA |
| Focus |
Immuno-neurology, neurodegenerative diseases |
| Status |
Public company |
| Year |
Event |
Amount |
| 2019 |
IPO |
~$120 million |
| 2021 |
Series C |
$226 million |
| 2024 |
Series D |
$150 million |
| Attribute |
Value |
| Mechanism |
Progranulin antibody |
| Indication |
Alzheimer's disease |
| Phase |
Phase 2 |
| Partner |
GSK (50-50 US profit share, tiered double-digit royalties ex-US) |
AL101 is Alector's lead clinical program, designed to increase progranulin levels. Developed in collaboration with GSK with U.S. 50-50 profit share and co-promote with tiered double-digit royalties outside the US.
| Attribute |
Value |
| Mechanism |
TREM2 agonist with Alector Brain Carrier (ABC) |
| Indication |
Alzheimer's disease |
| Phase |
Phase 2 (INVOKE-1 Trial) |
| Partner |
Roche |
| Attribute |
Value |
| Mechanism |
Anti-amyloid beta antibody with ABC |
| Indication |
Alzheimer's disease |
| Stage |
Preclinical |
| Attribute |
Value |
| Mechanism |
GCase enzyme replacement therapy with ABC |
| Indications |
Parkinson's disease, Gaucher disease, Dementia with Lewy Bodies |
| Stage |
Preclinical |
| Program |
Mechanism |
Indication |
Stage |
| AL064-ABC |
Tau-siRNA |
Alzheimer's disease, FTD |
Research |
| ADP062-ABC |
α-Syn-siRNA |
Parkinson's disease |
Research |
| ADP065-ABC |
NLRP3-siRNA |
Neuroinflammation in AD and PD |
Research |
Alector's proprietary ABC platform enables delivery of therapeutics across the blood-brain barrier:
- Brain Targeting: Enhanced delivery to central nervous system
- Multiple Modalities: Antibodies, enzymes, siRNA
- Versatility: Platform applicable across multiple programs
Alector's immuno-neurology platform focuses on:
- TREM2 Agonists: Activating TREM2 receptors on microglia to enhance amyloid clearance
- Progranulin Modulators: Increasing progranulin levels to address genetic forms of neurodegeneration
- Immune System Reprogramming: Harnessing the brain's immune system to clear pathological proteins
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on microglia that plays a critical role in the brain's immune response to amyloid plaques. Mutations in TREM2 are associated with increased risk of Alzheimer's disease. Alector's TREM2 agonists aim to:
- Enhance microglial activity
- Improve clearance of amyloid-beta plaques
- Reduce neuroinflammation
Progranulin is a protein that helps regulate lysosomal function and immune responses. Loss-of-function mutations in the GRN gene lead to reduced progranulin and cause frontotemporal dementia. AL001 and AL101 aim to increase progranulin levels to restore normal lysosomal function.
- Phase 3 trial in patients with biomarker-positive Alzheimer's disease
- Targeting patients with elevated amyloid and/or tau biomarkers
- Discontinued in 2024
- Phase 2 trial evaluating AL002 in early Alzheimer's disease
- Partnership with Roche for development and commercialization
- Phase 2 trials for Alzheimer's disease
- Ongoing collaboration with GSK
- Arnon Rosenthal (Co-founder and CEO)
- Dr. Robert W. (Chief Scientific Officer)
- Dr. Sarah M. (Chief Medical Officer)
- GSK: AL101 collaboration (50-50 US profit share)
- Roche: AL002 strategic partnership
- Multiple academic collaborations for biomarker development
¶ Competitive Landscape
| Company |
Drug |
Target |
Status |
| Alector |
AL101 |
Progranulin |
Phase 2 |
| Alector |
AL002 |
TREM2 |
Phase 2 |
| Eli Lilly |
Donanemab |
Amyloid |
Approved |
| Eisai/Biogen |
Leqembi |
Amyloid |
Approved |
| Biogen |
BIIB080 |
Tau ASO |
Phase 1/2 |
Alector's programs target key mechanisms in neurodegenerative diseases: